Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
COVID-19, is a highly transmittable and pathogenic human coronavirus that first emerged in …

Despite tremendous efforts in the past two years, our understanding of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), virus–host interactions, immune …

The continued emergence of highly pathogenic viruses, which either thwart immune-and
small molecule-based therapies or lack interventions entirely, mandates alternative …

Because of its scale and suddenness, the SARS-CoV-2 pandemic has created an
unprecedented challenge in terms of drug development. Apart from being natural …

The COVID‐19 pandemic has been a public health emergency, with deadly forms constantly
emerging around the world, highlighting the dire need for highly effective antiviral …

The ORF3a is a large accessory protein in severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which plays an important role in virulence and viral replication; especially in …

The L84S mutation has been observed frequently in the ORF8 protein of SARS-CoV-2,
which is an accessory protein involved in various important functions such as virus …

The continuing emergence of variants of the SARS-CoV-2 virus requires the development of
modular molecular therapies. Here, we engineered a recombinant amphiphilic protein …

Nucleoprotein is a conserved structural protein of SARS-CoV-2, which is involved in several
functions, including replication, packaging, and transcription. In this research, 21 antiviral …

ORF3a is a conserved accessory protein of SARS-CoV-2, linked to viral infection and
pathogenesis, with acquired mutations at various locations. Previous studies have shown …